At the request of Congress, in 2008 NIH began releasing to the public how much the agency spends in various research categories. I decided to pick out the top-funded disease areas to get a sense of what disorders and diseases the U.S. government is prioritizing. The red and green arrows indicate whether categories had a decrease or bump in funding from the previous year, respectively.
In an era of massive clinical trial failures and R&D cutbacks in Big Pharma, drug developers are searching for ways to test drug candidates more accurately and cost-efficiently before pouring millions of dollars into clinical trials. New technology like organs-on-chips and bioprinted tissues have the potential to test the safety of drugs more effectively for a myriad of diseases.
Organizations from both the private sector and academia are working on such technology to help drug developers advance new therapies toward FDA approval.
FierceBiotech is now available on iPhone and iPad!
This is the best FierceBiotech reading experience we've ever created. Swipe right-to-left within articles to quickly scan the latest news. Get breaking news alerts sent to your mobile device so you're the first to know when a major story unfolds. Download it today; the app is an essential complement to our e-mail newsletter and website.
Android users: We're on track to have an app complete by the end of the year.
Have something to say? Join the conversation at
FierceBiotech's LinkedIn group.
POPULAR COMMENT THREADS
For William Strohl, the new head of Janssen's Biotechnology Center of Excellence, the future of drug R&D involves novel targets, "fit-for-purpose" antibodies and lots of collaborations.
Mesenchymal stem cells may eventually be able to grow and strengthen muscles in humans, according to researchers at the University of Illinois. In mice, an injection of such stem cells helped rejuvenate skeletal muscle after exercise.
Scientists at Washington University in St. Louis have discovered one method by which malaria parasites resist drugs.
The National Institutes of Health is launching three new programs in emerging areas with the lofty goal of transforming biomedical research in the next 5 to 10 years.
An experimental anti-inflammatory drug delivered via a shot in the skin prevents neuron loss in rats with Parkinson's disease, according to a new study by researchers from Emory University School of Medicine in Atlanta.
In response to back-to-back incidents involving government laboratories, a top official at the U.S. Centers for Disease Control and Prevention has resigned, and the agency has assembled a safety board to address concerns that have arisen after workers were potentially exposed to anthrax and H5N1 flu.
From Our Sister Sites
Long cleared by the FDA, Zeltiq Aesthetics' fat-freezing CoolSculpting technology gained enough traction last quarter to catapult the company to a surprise profit. The company was so confident, it also raised its 2014 guidance.
Boston Scientific scored a victory in its ongoing transvaginal mesh saga, winning the first case to go to trial in Massachusetts state court.